15
Feb
2022
Watch
Strengthening Europe in the fight against cancer(debate)
Dear President, Commissioner, dear Veronica, Europe must first be effective in solving problems that are important to its citizens, so I am really pleased that the European Parliament can contribute with its report to a common European cancer initiative. And this is a diagnosis that brings more than a million Europeans to the grave every year, and this figure can be significantly reduced through prevention, screening, and early diagnosis and treatment. Money is needed everywhere, but also, of course, the political will to act together. However, I would like to draw attention here today to one aspect, namely the inequality in the diagnosis and treatment of cancer between European countries. Let us be honest, there are now huge differences between countries in Europe in terms of early detection, access to modern medicines and treatments, and quality follow-up care. And I think that this aspect of inequality must actually be at the heart of Europe's cancer plan. And no European initiative will be successful if only the citizens of a few Member States benefit from it. It is by doing and organising many things together that we can achieve better cancer care for all patients in all Member States. I would therefore like to highlight those initiatives in the plan that most directly affect this aspect of inequality. First of all, equal access to screening must be achieved in all Member States, as today differences, such as breast cancer screening, are even tenfold between countries. In addition, equivalent quality standards for screening should also be introduced. Secondly, the European Commission must work actively with the Member States to achieve equal access to innovative medicines. There is a need for effective competition between pharmaceutical manufacturers to reduce costs and increase access to medicines, and for joint European procurement. That is why our report also stresses that patients have the right to optimal treatment, regardless of their ability to pay, country of origin, age and gender. Finally, comprehensive cancer centres in the Member States need to set up a network at European level to serve both the circulation of medical data and to give patients access to the best diagnostics and expertise. These centres must also serve, of course, as a basis for joint research. And finally, the envisaged Cancer Inequalities Registry will only be relevant if we see it as a guideline for joint work and common deliverables.